Different chemical proteomic approaches to identify the targets of lapatinib

References

• Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, et al. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia. 2011;13(11):1026–1034.
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Scholten A, Heck AJR. Revealing promiscuous drug–target interactions by chemical proteomics. Drug Discov Today. 2009;14(21–22):1021–1029.
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Drewes G. Chemoproteomic approaches to drug target identification and drug profiling. Bioorg Med Chem. 2012;20(6):1973–1978.
   PubMed Web of Science ®Google Scholar
• Wang K, Yang T, Wu Q, Zhao X, Nice EC, Huang C. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev Proteomics. 2012;9(3):293–310.
   PubMed Web of Science ®Google Scholar
• Sutton CW. The role of targeted chemical proteomics in pharmacology. Br J Pharmacol. 2012;166(2):457–475.
   PubMed Web of Science ®Google Scholar
• Leslie BJ, Hergenrother PJ. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem Soc Rev. 2008;37(7):1347–1360.
   PubMed Web of Science ®Google Scholar
• Hatanaka Y. Development and leading-edge application of innovative photoaffinity labeling. Chem Pharm Bull. 2015;63(1):1–12.
   PubMed Web of Science ®Google Scholar
• Robinette D, Neamati N, Tomer KB, Borchers CH. Photoaffinity labeling combined with mass spectrometric approaches as a tool for structural proteomics. Expert Rev Proteomics. 2006;3(4):399–408.
   PubMed Web of Science ®Google Scholar
• Lapinsky DJ. Tandem photoaffinity labeling–bioorthogonal conjugation in medicinal chemistry. Bioorg Med Chem. 2012;20(21):6237–6247.
   PubMed Web of Science ®Google Scholar
• Kool J, Jonker N, Irth H, Niessen WMA. Studying protein-protein affinity and immobilized ligand-protein affinity interactions using MS-based methods. Anal Bioanal Chem. 2011;401(4):1109–1125.
   PubMed Web of Science ®Google Scholar
• Petrov KG, Zhang Y-M, Carter M, Cockerill GS, Dickerson S, Gauthier CA, Guo Y, Mook RA, Rusnak DW, Walker AL, et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett. 2006;16(17):4686–4691.
   PubMed Web of Science ®Google Scholar
• Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Therapeut. 2001;1:85–94.
   PubMed Web of Science ®Google Scholar
• Yamaura K, Kuwata K, Tamura T, Kioi Y, Takaoka Y, Kiyonaka S, Hamachi I. Live cell off-target identification of lapatinib using ligand-directed tosyl chemistry. Chem Commun. 2014;50(91):14097–14100.
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib). Cancer Res. 2004;64(18):6652–6659.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425.
   PubMed Web of Science ®Google Scholar
• Wiley SH. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol. 1988;107(2):801–810.
   PubMed Web of Science ®Google Scholar
• Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol. 2009;5(9):616–624.
   PubMed Web of Science ®Google Scholar
• Hwang H‐Y, Kim TY, Szász MA, Dome B, Malm J, Marko‐Varga G, Kwon HJ. Profiling the protein targets of unmodified bio‐active molecules with drug affinity responsive target stability and liquid chromatography/tandem mass spectrometry. Proteomics. 2020;20(9):1900325.
   Web of Science ®Google Scholar
• Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat Rev Drug Discov. 2022;21(9):637–654.
   PubMed Web of Science ®Google Scholar
• Nujić K, Smith M, Lee M, Belamarić D, Tomašković L, Alihodžić S, Malnar I, Polančec D, Schneider K, Eraković Haber V, et al. Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities. Eur J Pharmacol. 2012;677(1–3):163–172.
   PubMed Web of Science ®Google Scholar
• Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem. 1996;68(5):850–858.
   PubMed Web of Science ®Google Scholar